Table 2. Perioperative details and complications of those in the TAH and Bi-HVAD groups.
| Perioperative details | TAH | Bi-HVAD | Overall | P value | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | Patients (n/N) | Pooled [95% CI] | I2 (%) | No. of studies | Patients (n/N) | Pooled [95% CI] | I2 (%) | No. of studies | Patients (n/N) | Pooled [95% CI] | I2 (%) | ||||
| Length of ICU stay (days) | 2 | 55 | 42 [0; 93] | 0 | 2 | 24 | 18 [1.9; 35] | 0 | 4 | 79 | 20 [5; 36] | 0 | 0.4 | ||
| Complications | |||||||||||||||
| Stroke (%) | 4 | 26/246 | 11 [7; 16] | 17 | 2 | 1/15 | 13 [2; 51] | 18 | 6 | 27/261 | 11 [8; 16] | 0 | 0.86 | ||
| AKI (%) | 2 | 30/84 | 28 [2; 89] | 95* | 1 | 3/11 | 27 [9; 59] | N/A | 3 | 33/95 | 28 [5; 74] | 91* | 0.98 | ||
| Cardiac reoperation (%) | 4 | 61/198 | 33 [18; 51] | 80* | 1 | 2/4 | 50 [12; 88] | N/A | 5 | 63/202 | 34 [20; 51] | 74 | 0.5 | ||
| Bleeding (all) (%) | 4 | 82/198 | 42 [28; 58] | 71* | 1 | 3/13 | 23 [8; 52] | NA | 5 | 85/211 | 40 [27; 54] | 67* | 0.22 | ||
| GI bleed (%) | 1 | 3/42 | 7 [2; 20] | N/A | 2 | 3/15 | 20 [7; 47] | 0 | 3 | 6/57 | 12 [5; 24] | 0 | 0.18 | ||
| Neurologic complications (%) | 2 | 20/143 | 14 [9; 21] | 0 | 1 | 2/13 | 15 [4; 45] | N/A | 3 | 22/156 | 14 [10; 21] | 0 | 0.91 | ||
| Overall infections (%) | 3 | 105/156 | 67 [47; 82] | 74* | 2 | 9/24 | 36 [10; 74] | 67 | 5 | 114/180 | 57 [38; 75] | 74* | 0.16 | ||
| Mediastinitis (%) | 5 | 12/325 | 4 [2; 7] | 0 | 1 | 2/13 | 15 [4; 45] | N/A | 6 | 14/338 | 5 [3; 8] | 0 | 0.07 | ||
| Driveline infection (%) | 3 | 10/97 | 11 [6; 18] | 0 | 1 | 1/13 | 8 [1; 39] | N/A | 4 | 11/110 | 10 [6; 18] | 0 | 0.73 | ||
*, heterogeneity P<0.05 (significant data heterogeneity present). TAH, total artificial heart; Bi-HVAD, biventricular HeartWare ventricular assist device.